WO2008064815A3 - Preparation for transdermally administering galanthamine - Google Patents

Preparation for transdermally administering galanthamine Download PDF

Info

Publication number
WO2008064815A3
WO2008064815A3 PCT/EP2007/010112 EP2007010112W WO2008064815A3 WO 2008064815 A3 WO2008064815 A3 WO 2008064815A3 EP 2007010112 W EP2007010112 W EP 2007010112W WO 2008064815 A3 WO2008064815 A3 WO 2008064815A3
Authority
WO
WIPO (PCT)
Prior art keywords
preparation
galanthamine
transdermally administering
transdermally
administering galanthamine
Prior art date
Application number
PCT/EP2007/010112
Other languages
German (de)
French (fr)
Other versions
WO2008064815A2 (en
Inventor
Frank Becher
Thomas Hille
Original Assignee
Lohmann Therapie Syst Lts
Frank Becher
Thomas Hille
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lohmann Therapie Syst Lts, Frank Becher, Thomas Hille filed Critical Lohmann Therapie Syst Lts
Publication of WO2008064815A2 publication Critical patent/WO2008064815A2/en
Publication of WO2008064815A3 publication Critical patent/WO2008064815A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention relates to a preparation for transdermally administering galanthamine. Said preparation is characterized in that galanthamine or one of the pharmaceutically acceptable salts thereof is made to be transdermally resorbed in a non-oily emulsion containing lecithin, oleic acid, and cholesterol.
PCT/EP2007/010112 2006-12-01 2007-11-22 Preparation for transdermally administering galanthamine WO2008064815A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006056783.8 2006-12-01
DE102006056783A DE102006056783A1 (en) 2006-12-01 2006-12-01 Preparation for the transdermal administration of galanthamine

Publications (2)

Publication Number Publication Date
WO2008064815A2 WO2008064815A2 (en) 2008-06-05
WO2008064815A3 true WO2008064815A3 (en) 2008-07-17

Family

ID=39247230

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/010112 WO2008064815A2 (en) 2006-12-01 2007-11-22 Preparation for transdermally administering galanthamine

Country Status (2)

Country Link
DE (1) DE102006056783A1 (en)
WO (1) WO2008064815A2 (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004002402A2 (en) * 2002-05-21 2004-01-08 Nastech Pharmaceutical Company Inc. Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid
US20040185170A1 (en) * 2003-03-21 2004-09-23 Shubha Chungi Method for coating drug-containing particles and formulations and dosage units formed therefrom
US20050074487A1 (en) * 1999-12-16 2005-04-07 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
WO2005039531A1 (en) * 2003-10-10 2005-05-06 Antares Pharma Ipl Ag Transdermal pharmaceutical formulation for minimizing skin residues
WO2005102268A2 (en) * 2004-04-22 2005-11-03 Sanochemia Pharmazeutika Ag Cholinesterase inhibitors in liposomes and their production and use
WO2007016766A1 (en) * 2005-08-05 2007-02-15 Nuvo Research Inc. Transdermal drug delivery formulation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9007052D0 (en) * 1990-03-29 1990-05-30 Skua Investments Ltd Pharmaceutical formulations
US5945409A (en) * 1995-03-10 1999-08-31 Wilson T. Crandall Topical moisturizing composition and method
HU227182B1 (en) * 2000-03-06 2010-09-28 Andras Javor Lecitin-ascorbic acid combination

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050074487A1 (en) * 1999-12-16 2005-04-07 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
WO2004002402A2 (en) * 2002-05-21 2004-01-08 Nastech Pharmaceutical Company Inc. Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid
US20040185170A1 (en) * 2003-03-21 2004-09-23 Shubha Chungi Method for coating drug-containing particles and formulations and dosage units formed therefrom
WO2005039531A1 (en) * 2003-10-10 2005-05-06 Antares Pharma Ipl Ag Transdermal pharmaceutical formulation for minimizing skin residues
WO2005102268A2 (en) * 2004-04-22 2005-11-03 Sanochemia Pharmazeutika Ag Cholinesterase inhibitors in liposomes and their production and use
WO2007016766A1 (en) * 2005-08-05 2007-02-15 Nuvo Research Inc. Transdermal drug delivery formulation

Also Published As

Publication number Publication date
DE102006056783A1 (en) 2008-06-05
WO2008064815A2 (en) 2008-06-05

Similar Documents

Publication Publication Date Title
WO2010150995A3 (en) Compositions for treating drug addiction and improving addiction-related behavior
WO2008070149A3 (en) Prodrugs and methods of making and using the same
WO2007126964A3 (en) Kinase inhibitors
EP2562177A3 (en) Transdermally deliverable buprenorphine prodrugs and abuse-resistant compositions thereof
WO2007135193A3 (en) Sustained-release alcohol-resistant multimicroparticulate oral pharmaceutical form comprising anti-misuse means
WO2008061226A3 (en) Sustained-release formulations of topiramate
WO2010041017A3 (en) Chewable gelled emulsions
WO2005107711A3 (en) Method and composition for treating rhinitis
WO2007018588A8 (en) Stable pharmaceutical composition comprising linezolid form iv
WO2009045795A3 (en) Galenical formulations of aliskiren and valsartan
WO2010090494A3 (en) Medical use of 5-benzylaminosalicylic acid derivatives or salts thereof
EP1902715A3 (en) Use of paliperidone for the treatment of psychiatric patients with reduced hepatic function
MX2009012782A (en) Formulations for the oral administration of therapeutic agents and related methods.
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
EP2392335A3 (en) Use of 24-norUDCA
WO2005120518A3 (en) Use of atp analogues for treatment of cardiovascular diseases
WO2009045053A3 (en) A cancer sensitizer comprising chlorogenic acid
WO2008051527A3 (en) Sustained release of agents for localized pain management
WO2006015970A3 (en) Medicaments for the prevention or treatment of alveolar pneumonia comprising an anticholinergic
WO2007134085A3 (en) Isothiazolidines useful in the treatment of ocular hypertensive conditions
WO2008063847A3 (en) Method for treating autism
WO2006128152A3 (en) Method to treat and prevent posterior capsule opacification
WO2006079625A3 (en) Medicaments for the prevention or treatment of heart failure comprising administration of an anticholinergic
WO2008061671A3 (en) Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels
WO2008125940A3 (en) Nanoparticles comprising non-crystalline drug

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07856217

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2007856217

Country of ref document: EP

122 Ep: pct application non-entry in european phase

Ref document number: 07856217

Country of ref document: EP

Kind code of ref document: A2